Dr. Matthew W. Manry, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of South Florida College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 715
Licensed in Colorado since 2018, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of South Florida College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
CO license DR.0060309 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Longmont United Hospital Longmont, CO
Medical groups
- Eye Care Center of Northern Colorado, PC (16 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 715
- Services billed
- 35,925
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,960 | 87 |
| Imaging of retina | 1,181 | 436 |
| Injection of drug into eye | 902 | 215 |
| Established patient office or other outpatient visit, 20-29 minutes | 731 | 354 |
| Photography of the retina | 605 | 387 |
| Injection, aflibercept, 1 mg | 600 | 79 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 390 | 18 |
| Established patient complete exam of visual system | 380 | 306 |
| Compounded drug, not otherwise classified | 287 | 72 |
| Established patient office or other outpatient visit, 30-39 minutes | 233 | 155 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Longmont, CO | 116 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Longmont, CO | 56 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 55 |
| Ketorolac Tromethamine Other prescribers in Longmont, CO | 34 |
| Latanoprost Other prescribers in Longmont, CO | 17 |
| Brimonidine Tartrate Other prescribers in Longmont, CO | 15 |
| Atropine Sulfate | 12 |
| Timolol Maleate Other prescribers in Longmont, CO | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 25 payments worth $810 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $398 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $119 |
| Genentech, Inc. | $96.47 |
| Mallinckrodt Hospital Products Inc. | $51.44 |
| Ani Pharmaceuticals, Inc. | $34.91 |
| Rxsight Inc | $26.95 |
| Sun Pharmaceutical Industries Inc. | $23.25 |
| Genentech USA, Inc. | $22.83 |
| Food and Beverage | $521 |
|---|---|
| Consulting Fee | $289 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Apellis Pharmaceuticals, Inc. Feb 14, 2025 | Consulting Fee Syfovre · Ophthalmology | $289 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $96,491 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - IAMD Observational Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.